Pharma offense is best reform defense

You know that pharma is joining the health-reform effort this time around, probably because company execs know they can't beat it completely. And you know that they're using that seat at the table to promote changes that they consider pharma-friendly. For lots more on drugmakers' offense-is-the-best-defense approach, check out the Wall Street Journal analysis. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.